Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Why Industry Should Model and De-Risk its Pharma Supply Chains

This article was originally published in The Gold Sheet

Executive Summary

As new biotech drugs come on the market, they will require supply chains that are more agile but less efficient. AstraZeneca’s MedImmune biologics unit looks to boost agility by modeling its supply chains and using a neural network to de-risk them.


Related Content

Enbrel Supply Interruption Will Be Resolved By June, Immunex Says





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts